David Valcárcel-Ferreiras

21PUBLICATIONS
148CO-AUTHORS
Regenerative medicine (incl. stem cells)Medical mycologyGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Aug 27, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

|Jul 17, 2026
Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.

|Jun 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|May 30, 2026
Switching patients with immune thrombocytopenia (ITP) to avatrombopag from other thrombopoietin receptor agonists: The real-world experience of the Spanish ITP Group (GEPTI).

|Apr 30, 2026
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

|Mar 28, 2026
Navigating the Hemostatic Balance: Anticoagulation and Antiplatelet Therapy in Patients with Thrombocytopenia.

María-Eva Mingot-Castellano, María Teresa Álvarez Román, Jose María Bastida

Pageof 4

Frequent Collaborators

5 joint publications

María Díez-Campelo

5 joint publications

Francesc Solé

5 joint publications

Valeria Santini

4 joint publications

Francesc Bosch